Faron Pharmaceuticals Ltd: Notice of Half-Year Financial Results 2026
CompaniesFaron Pharmaceuticals Ltd
Signals
Every pharma-relevant, de-duplicated event surfaced so far, primary source first. Client-scoped signals are never shown here.
Amylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, more
CompaniesAmylyxSummit TherapeuticsAkesoDefiniumNeurocrine BiosciencesEli LillyAssetsavexitideivonescimabVykatretatrutideDiseasespost-bariatric hypoglycemiageneralized anxiety disordersquamous non-small cell lung cancerPrader-Willi syndrome
Andelyn Biosciences to Implement Curator® Platform to Develop and Manufacture Gene Therapy AAV9-GM2 for Queen's University to Treat GM2 Gangliosidoses
CompaniesAndelyn BiosciencesQueen's UniversityAssetsAAV9-GM2DiseasesGM2 gangliosidosesTay-Sachs diseaseSandhoff disease
Enrolment concludes in Lynch’s Phase II rhPDGF-BB study
CompaniesLynch Regenerative MedicineAssetsrhPDGF-BBDiseasesskin cancer
Abcuro secures $66m to support clinical trial of ulviprubart for IBM
CompaniesAbcuroNew Leaf Venture PartnersBain Capital Life SciencesEurofarma VenturesForesite CapitalKaitai CapitalMass General Brigham VenturesPontifaxRA Capital ManagementRedmile GroupSamsara BioCapitalSanofi VenturesShang BaySoleus CapitalRock Springs CapitalAssetsulviprubartDiseasesinclusion body myositis
Car emissions crackdown in London improves child health
Mercado farmacêutico chega a R$ 279,7 bilhões
[Reporter's Notebook] In Korea, medical AI approval outpaces reimbursement
CompaniesKorea's medical AI companies
BeOne Medicines and partners renew Brukinsa access programme for CLL
CompaniesBeOne MedicinesThe Max FoundationAssetsBrukinsaDiseaseschronic lymphocytic leukaemia (CLL)
AI takes center stage in hospital transformation as KHF 2026 opens
Olfactory dysfunction linked to 19% higher risk of migraine, study finds
Diseasesmigraine
'Despite slogan to save essential care, front-line health workers fear burnout and departures'
China’s ADC surge pushes IntoCell toward pipeline-focused licensing strategy
CompaniesIntoCellSamsung BioepisAssetsOHPASPMTNexatecaniso-NexatecanTBA linkerITC-6146RO5T4 ADCDLL3 ADCPSMA ADCHER3 ADCDiseasesB7-H35T4prostate cancerHER3
EyePoint shares plummet after phase 3 stumble for AMD drug-device combo Duravyu
CompaniesEyePointRegeneron PharmaceuticalsBayerAssetsDuravyuEyleaDiseaseswet age-related macular degeneration
2 sources — primary and 1 also reporting
BMI Alone Questioned for Predicting Mortality Risk in Seniors
Reformed pharmaceutical regulation across India’s drug landscape
Sam Chun Dang clears Eylea patent disputes as SCD411 exports grow
CompaniesSam Chun Dang PharmRegeneron PharmaceuticalsBayer Consumer CareAssetsSCD411Eylea 2 mg (aflibercept)
Yonsei expands heavy ion therapy to head and neck cancer, sarcoma, recurrent rectal cancer
CompaniesYonsei Cancer CenterDiseaseshead and neck cancersarcomarecurrent rectal cancer
Two physicians at The Wall Center named to America's Best Plastic Surgeons 2026 — a first for any Shreveport practice
CompaniesThe Wall Center for Plastic Surgery
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CompaniesCytokinetics